Bristol-Myers Squibb is having a busy holiday period, signing a $4.1 billion deal to acquire cancer drug developer RayzeBio – its second multibillion-dollar M&A deal in the space of a week. BMS is ...

Bristol-Myers Squibb's flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them with its cancer immunotherapy ...